Actelion aims to discover or in-license and develop a steady stream of new products as revenue sources based on first-in-class small molecule compounds. In doing so, Actelion is focusing on innovative treatments for highunmet medical needs, where Actelions new drugs can bring therapeutic advantage to patients and economic benefit for the community at large. Actelion also aims to maximize the value of its products, for example, by seeking additional indications for existing drugs.

Actelion has established an infrastructure to develop, register and market its products in key markets worldwide. By doing so, Actelion is generating sustained profitability and ensuring a growth above industry average. When a product's potential indications could serve a patient population so large that Actelion could not adequately serve it with its own marketing force, the company may seek strategic partnerships with other pharmaceutical or biopharmaceutical companies.